Covid-19 (Temas de Saúde Pública)
Efeitos da vacinação na transmissão domiciliar do SARS-CoV-2 na Inglaterra – “A probabilidade de transmissão domiciliar foi de aproximadamente 40 a 50% menor em familiares de pacientes-índice vacinados 21 dias ou mais antes do teste positivo do que os familiares de pacientes-índice não vacinados.”
24 Jun, 2021 | 11:04hRelacionados: Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose E Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.
Perspectiva | Variante Delta aciona uma nova e perigosa fase da pandemia.
24 Jun, 2021 | 11:03hDelta variant triggers dangerous new phase in the pandemic – Science
CDC | Vacinas de mRNA parecem ter ligação com casos de miocardite e pericardite – 1.226 casos de miocardite ou pericardite foram relatados, a maioria em pessoas com menos de 30 anos de idade.
24 Jun, 2021 | 11:00hVer também: Experts: mRNA COVID-19 vaccines likely tied to heart inflammation – CIDRAP
Relacionados: Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination. E Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination. E Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination. E CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Análise | O futuro dos preços das vacinas contra Covid-19: lições da influenza – “Uso rotineiro de vacinas contra Covid-19 pode sobrecarregar os orçamentos de saúde se os preços seguirem o mesmo padrão das vacinas contra Influenza.”
24 Jun, 2021 | 10:59hFuture of covid-19 vaccine pricing: lessons from influenza – The BMJ
Comentário no Twitter
In case you're assuming the price of Covid vaxes is going to go down, this group is here with bad news from the trajectory of flu vaxes: the more there are, the higher the prices go. Just great. 😧 From @jasonlschwartz & co https://t.co/66QHwazmES
— Hilda Bastian, PhD (@hildabast) June 22, 2021
Infográfico interativo | Interpretação do fluxo lateral do teste de antígeno contra SARS-CoV-2 – “Esta calculadora mostra como a interpretação do resultado do dispositivo de fluxo lateral (lateral flow device – LFD) da Covid-19 pode variar de acordo com a probabilidade pré-teste e a sensibilidade e a especificidade do LFD utilizado.”
23 Jun, 2021 | 11:00hInterpreting a lateral flow SARS-CoV-2 antigen test – The BMJ
Variante Delta do coronavírus: cientistas se preparam para o impacto.
23 Jun, 2021 | 10:59hDelta coronavirus variant: scientists brace for impact – Nature
Nova análise revela ligação entre comemorações de aniversários e disseminação de COVID-19 durante o pico da pandemia.
23 Jun, 2021 | 10:56hComunicado de imprensa: New Analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic – Harvard Medical School
Estudo original: Assessing the Association Between Social Gatherings and COVID-19 Risk Using Birthdays – JAMA Internal Medicine
Comentário no Twitter (fio – clique para saber mais)
The link between birthdays and Covid-19
Thread on our new study (w/ @CM_Whaley, Jon Cantor, Megan Pera) in @JAMAInternalMed
Using data on ~3M households, households in which a member had bday 2 wks prior were ~30% more likely to have a covid diagnosishttps://t.co/KHCvGAlvox
— Anupam Jena (@AnupamBJena) June 21, 2021
[Preprint] Rápida substituição da variante B.1.1.7 (Alfa) do SARS-CoV-2 pelas variantes B.1.617.2 (Delta) e P.1 (Gama) nos Estados Unidos.
22 Jun, 2021 | 09:14hRapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv
Comentário no Twitter
🆕💥💥Preprint
📌B.1.617.2 Delta and P.1 are growing faster than B.1.1.7 & B.1.617.2 is growing faster than P.1 in the US
📌B.1.617.2 will soon be the dominant variant in the US
📌B.1.617.2 is growing more rapidly in counties with lower vaccination rateshttps://t.co/6Rf3p5N4ed pic.twitter.com/sVzyQRXn12— Antibiotic Steward 🇵🇸💔Bassam Ghanem (@ABsteward) June 22, 2021
Perspectiva | COVID-19: ascensão e ascensão de Delta.
22 Jun, 2021 | 09:13hCOVID-19: The rise and rise of Delta – Sciblogs
Ivermectina é a nova hidroxicloroquina, parte 2 – “Ivermectina não deve ser usada no tratamento da COVID-19 fora do contexto de um estudo clínico.”
22 Jun, 2021 | 09:11hIvermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine
Relacionado: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance E M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection E Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials E EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials E FDA: Why you should not use Ivermectin to treat or prevent COVID-19 E RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 E NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” E Video (5min): Ivermectin for COVID-19 | A Doctor Explains